Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction-associated steatohepatitis?

Diabetes, obesity & metabolism2026PMID: 41556066

Authors

Polyzos, Stergios A; Kountouras, Jannis; Duntas, Leonidas H; Targher, Giovanni

Keywords

glucagon‐like peptide‐1 receptor agonistmetabolic dysfunction‐associated steatohepatitismetabolic dysfunction‐associated steatotic liver diseaseresmetiromsemaglutidethyroid hormone receptor‐β agonist